benserazide has been researched along with Anxiety in 2 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Anxiety: Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loiodice, S | 1 |
| Wing Young, H | 1 |
| Rion, B | 1 |
| Méot, B | 1 |
| Montagne, P | 1 |
| Denibaud, AS | 1 |
| Viel, R | 1 |
| Drieu La Rochelle, C | 1 |
| Gerlach, J | 1 |
| Lühdorf, K | 1 |
1 trial available for benserazide and Anxiety
| Article | Year |
|---|---|
The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.
Topics: Adult; Affect; Antipsychotic Agents; Anxiety; Basal Ganglia Diseases; Benserazide; Brief Psychiatric | 1975 |
1 other study available for benserazide and Anxiety
| Article | Year |
|---|---|
Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Topics: Amphetamine; Animals; Antiparkinson Agents; Anxiety; Benserazide; Disease Models, Animal; Dopamine; | 2019 |